Fatty Liver Scan — Why Elastography Is Better Than a CT Scan

A CT (computed tomography) scan creates detailed cross-sectional images of the body using X-rays. It can identify many liver conditions — tumours, abscesses, haemorrhage, and gross anatomical abnormalities.

For fatty liver disease specifically, a CT scan can detect significant hepatic steatosis. A liver with substantial fat content appears darker (lower density) than normal liver tissue on CT — a finding reported as hepatic steatosis or fatty infiltration.

What CT can detect:

• Significant liver fat accumulation (typically above 20–30% fat content)
• Liver tumours or masses
• Vascular abnormalities
• Cirrhotic changes in gross architecture
• Complications of advanced liver disease

What CT cannot detect:

• Liver fibrosis (scarring) — CT cannot measure liver stiffness or staging of fibrosis
• Mild to moderate steatosis (below 20% fat content may be missed)
• MASH (inflammation cannot be detected on CT imaging)
• Early fibrosis stages (F1, F2) that determine prognosis and treatment decisions

This last point is the critical limitation. The most important prognostic factor in MASLD is the degree of liver fibrosis — not the amount of fat. A patient with 30% liver fat and no fibrosis has a very different prognosis to a patient with 20% liver fat and F3 fibrosis. CT cannot distinguish between these two patients.

A standard abdominal CT delivers approximately 8–10 millisieverts (mSv) of radiation — equivalent to approximately 4 years of background radiation exposure.

For a single diagnostic CT in an adult, this level of radiation is generally considered acceptable. But for the repeated monitoring that MASLD requires — annual or biennial reassessment to track disease progression or treatment response — radiation accumulation becomes a meaningful consideration.

Liver elastography involves no radiation whatsoever. This makes it safe for repeated use across the years or decades of MASLD monitoring that many patients require.

Liver elastography — FibroScan, iLivTouch, or equivalent guided elastography systems — provides two measurements that CT simply cannot:

1. Liver stiffness (kPa) — Fibrosis staging: The mechanical pulse sent through the abdomen by an elastography device measures how stiff the liver is. Stiffer liver = more fibrosis. This is the single most important measurement in MASLD management. A liver stiffness below 8 kPa is generally reassuring for F0–F1. Above 13 kPa indicates the cirrhosis range. CT provides no equivalent measurement.

2. CAP score (dB/m) — Liver fat quantification: The controlled attenuation parameter quantifies liver fat content with a level of precision CT cannot match — detecting steatosis grades from S0 (normal, less than 5% fat) to S3 (severe, more than 67% fat). CT can detect gross steatosis but cannot grade it with this precision.

Both measurements are delivered in a single 10–15 minute session, with immediate results.

The Gastroenterological Society of Australia consensus statement and Australian Prescriber's 2026 MAFLD update both recommend liver ultrasound as the first-line test for diagnosing hepatic steatosis, followed by noninvasive testing for liver fibrosis in at-risk patients.

The fibrosis testing pathway recommended in Australian guidelines is:

1. FIB-4 score calculation from routine bloods (first line)
2. Liver elastography for indeterminate FIB-4 (1.3–2.67) (second line)
3. Liver biopsy for cases where non-invasive tests are inconclusive (rarely required)

CT is not part of this guideline pathway for MASLD assessment. Ultrasound is used for initial steatosis detection (it detects bright/echogenic liver from fat). Elastography is used for fibrosis staging. CT's role in MASLD management is primarily for excluding other pathology — tumours, vascular disease — not for staging the liver disease itself.

For MASLD assessment, liver elastography provides the most clinically relevant information at a reasonable cost, without radiation, without invasive procedure. The absence of a Medicare item number is the primary access barrier — something Australian advocacy groups are actively working to address.

CT scanning remains the appropriate investigation for:

• Excluding liver tumours or hepatocellular carcinoma in patients with cirrhosis
• Assessing liver vascular anatomy before hepatobiliary surgery
• Evaluating complications of advanced liver disease (portal hypertension, varices)
• Investigating acute abdominal pain where the diagnosis is unclear

For routine MASLD assessment, staging, and monitoring — elastography is the right tool.

Find a liver elastography clinic near you →